Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Canopy Growth CorporationNASDAQ: CGC

Depreciation & Amortization · Q4 FY2025 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q4 FY2025 depreciation & amortization of CA$8.65M fell 24.5% year over year, behind the -7.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 29.2% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.

Context

  • Depreciation & amortization amounted to 10.5% of revenue in FY2025, down 5.5 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -24.5% toward the trailing-twelve-month pace of -7.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$8.65M-29.2% QoQ
Last fiscal yearMar 2026
CA$50.86M+18.0% YoY
LTMMar 2026
CA$39.79M-7.7% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.5%——
1 year+18.0%——
3-year CAGR-14.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

CAD · from the cash flow

Latest · FY2025
50.86M CAD
Year-over-year change
+18.0%
4-year CAGR
-17.7%

Depreciation & Amortization vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.7% is the 5th highest of 9, against a peer median of -9.9%.
  • Depreciation & amortization amounts to 12.7% of revenue for CGC, versus a peer median of 6.8%.
CGC Competitors
Depreciation & Amortization for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DHDefinitive Healthcare Corp.LTM Mar 2026$55.54M USD+5.2%-0.5%23.3%
CGCCanopy Growth CorporationLTM Mar 2026CA$39.79M CAD-7.7%-14.0%12.7%
ACBAurora Cannabis Inc.LTM Mar 2026CA$14.19M CAD-37.1%-31.1%4.6%
LYELLyell Immunopharma, Inc.LTM Mar 2026$10.43M USD-42.2%-11.2%33645.2%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$9.76M USD—-23.7%7.2%
TKNOAlpha Teknova, Inc.LTM Mar 2026$6.34M USD-2.8%+26.1%15.2%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$2.79M USD+41.0%+9.9%0.8%
CABACabaletta Bio, Inc.LTM Mar 2026$1.5M USD-16.9%+11.8%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$528K USD-25.9%-17.1%6.3%
BIOABioAge Labs, Inc.LTM Mar 2026$239K USD+39.8%+18.2%2.3%
Peer median (excluding CGC) —-9.9%-0.5%6.8%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Net Income(258.91M)(3.08B)(483.68M)(604.14M)(366.64M)
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
Deferred Income Tax(8.95M)(5.73M)12.33M7.14M0
Stock-Based Compensation46.69M25.32M14.18M(4.21M)5.95M
Change in Working Capital205M58.97M3.97M(31.97M)20.68M
Accounts Receivables16.15M6.24M(3.75M)(4.49M)25.69M
Inventory204.22M68.44M1.03M(17.72M)3.71M
Accounts Payables00000
Other Working Capital(15.37M)(15.71M)6.68M(9.77M)(8.72M)
Other Non-Cash Items(640.58M)2.36B118.08M424.3M200.17M
Operating Cash Flow(545.81M)(557.55M)(281.95M)(165.75M)(88.98M)
Capital Expenditures(48.11M)(10.45M)(4M)(11.28M)(7.44M)
Acquisitions (Net)103.2M14.93M(955K)(6.97M)0
Purchases of Investments(379.41M)(67.15M)(347K)(95.34M)0
Sales of Investments546.01M502.59M78.55M16.43M26.5M
Other Investing Activities(2.3M)(7.88M)167.79M48.9M(48.83M)
Investing Cash Flow230.82M433.38M241.59M(47.79M)(29.77M)
Debt Repayment(50.76M)16.98M(509.78M)(220.78M)(24.62M)
Common Stock Issued2.7M1.05M81.06M385.39M374.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.53M(37.72M)(36.34M)(15.96M)114.02M
Financing Cash Flow(45.53M)(19.69M)(465.06M)148.66M463.57M
Effect of Forex Changes(18.12M)44.86M(1.29M)8.39M5.05M
Net Change in Cash(378.65M)(99M)(506.71M)(56.49M)349.86M
Free Cash Flow(593.92M)(568M)(285.95M)(177.03M)(96.42M)

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.